All In Biotech

NDA 021923 · Bayer Hlthcare

Nexavar

Sorafenib Tosylate · Oral · Kinase Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Dec 1, 2005

Approved uses

7

Original approval plus efficacy supplements

Registered trials

760

116 Phase 3, 24 recruiting

FAERS reports

20,631

18,369 serious, 5,085 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 28, 2023.

NEXAVAR is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) 1.1 Hepatocellular Carcinoma NEXAVAR ® is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Mechanism: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 22, 2017 Supplement 18 · Efficacy OrphanLetterLabel
  • Nov 22, 2013 Supplement 16 · Efficacy · priority review OrphanLabelLetter
  • Nov 16, 2007 Supplement 4 · Efficacy · priority review LabelLetter
  • Nov 16, 2007 Supplement 7 · Efficacy · priority review LabelLetter
  • Nov 16, 2007 Supplement 5 · Efficacy · priority review LabelLetter
  • Nov 16, 2007 Supplement 6 · Efficacy · priority review LetterLabel
  • Dec 1, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
1 products under this application
  • NEXAVAR · SORAFENIB TOSYLATE EQ 200MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sorafenib" as an intervention, any sponsor and status, largest first.

All 760 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea2,963
  • palmar-plantar erythrodysaesthesia syndrome2,170
  • hepatocellular carcinoma1,899
  • fatigue1,800
  • off label use1,710
  • death1,461
  • rash1,461
  • decreased appetite1,453
  • nausea1,367
  • asthenia1,186
  • hypertension1,152
  • pyrexia1,066

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200510
20061,014
2007812
2008848
20091,189
20101,615
20111,476
20121,401
2013912
20141,096
20151,356
20161,100
20171,477
20181,578
20191,030
2020798
2021703
2022562
2023640
2024537
2025291
2026186

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nexavar (Sorafenib Tosylate)

2024 spending

$4.3M

Beneficiaries

62

305 claims

Per beneficiary

$70,029

$189.08 per unit

View as table
YearSpending
2020$92,462,007
2021$76,544,741
2022$47,612,504
2023$8,471,542
2024$4,341,768

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,253 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.